International Journal of Biological Sciences · 2024 · 22 citations · 27 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCytotoxic T Lymphocyte ResponsesImmune Checkpoint InhibitorsMetabolic ReprogrammingMetabolic Reprogramming In CancerCd8 Positive T CellsCd8 T Cell ActivationEffector T Cell MetabolismImmune Checkpoint Inhibitor TherapyMtorc1 SignalingPcsk9 Inhibitor TherapyPcsk9 InhibitorsProgrammed Cell Death Protein 1 (Pd-1) Pathway
T cells. LDLR deficiency was shown to impair cellular mTORC1 signaling and the anti-HCC function of CD8 T cells. On the basis of our findings in this study, we propose a potential metabolic intervention strategy that could be used to enhance the antitumor effects of immunotherapy for HCC.
27
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Marianne Abifadel, Mathilde Varret, Jean‐Pierre Rabès et al. · Nature Genetics · 2003 · 3K citations
Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism
Wei Yang, Yibing Bai, Ying Xiong et al. · Nature · 2016 · 1K citations · Full text